Skip to main content

One-year estimated state impact to hospitals of 340B cuts for FFY 2021

The 340B Drug Pricing Program allows qualifying hospitals to offer affordable prescription drugs to financially vulnerable and fragile patients by purchasing outpatient drugs from manufacturers at a discounted rate. These hospitals then can reinvest the savings in their services.

In 2018, CMS issued a final Outpatient Prospective Payment System rule that reduced by approximately 25% the reimbursement for certain drugs that hospitals acquired through the 340B Program and then continued those cuts in 2019 through 2022. HHS' 340B cuts are currently being challenged through a lawsuit with the U.S. Supreme Court. 

This analysis includes the continued 3.19% budget-neutral adjustment and the 340B reduction (Average Sales Price minus 22.5%) that was identified in the Standard Analytic File with the “JG” modifier, resulting in a net impact. DataGen has analyzed the budget neutrality adjustment and 340B cuts utilizing the 2019 Standard Analytic File showing the potential impact to 340B hospitals.


DataGen reviews and analyzes major Medicare policy changes before and after they happen, creating easy-to-understand analyses to help our state hospital associations, their members and multi-state health systems advocate, adjust and strategize accordingly.
Labels:

Comments

Post a Comment

Popular posts from this blog

CMS Enhancing Oncology Model Updates: RFA Issued for Second Cohort

Key CMMI updates to the EOM  The Center for Medicare and Medicaid Innovation (CMMI) released exciting updates to the Enhancing Oncology Model (EOM) along with a new opportunity for a second cohort of participants.   The EOM aims to enhance the quality of care for cancer patients while reducing costs under the Medicare fee-for-service program. The updates come on the heels of lower-than-expected model participation .   This blog will discuss key EOM updates, application details, eligibility requirements and important deadlines.  New cohort opportunity  Request for applications: CMS issued an RFA to recruit a second cohort of participants and payers for the EOM.  Timeline:  Second cohort start date: July 1, 2025  Second cohort end date: June 30, 2030  Initial performance period start date: July 1, 2023  Model test end date for all participants: June 30, 2030 (extended from June 30, 2028)  Notable changes to the EOM model  Model extension: The model's duration is extended by two yea
Post a Comment
Read more

What does healthcare improvement look like in 2024 and beyond?

The healthcare industry has faced many new challenges in recent years. How does this seemingly ever-changing landscape impact healthcare improvement in 2024 and beyond? Based on the Institute for Healthcare Improvement 2023 Forum, quality improvement, safety and culture, equity and a functional delivery system remain top priorities across sectors. This was reflected in the forum agenda , which included 10 tracks and a scientific symposium with three primary focus areas: Quality: Addressing value, cost and quality; diagnostic excellence and improvement science Culture and safety: Building capability, leadership, workforce well-being and patient and workforce safety Patient focus: Equity, person-centered care and population health Since DataGen participated, we’ll give you some exclusive insight into what was discussed so you can better understand what’s driving healthcare in the new year. The future of healthcare improvement: 4 major insights 1. Quality requires a systems approach Th
Post a Comment
Read more